Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Using data from linked Swedish health-related registries, researchers examined outpatient antipsychotic use and ...

Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to ...

The fake psychiatrist diagnosed two young women suffering from anxiety as schizophrenic and with ‘narcissistic personality ...

Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

They can be caused by an unmet need – for example, hunger, thirst or discomfort – or a health problem such as an infection. People with these symptoms are often prescribed antipsychotic drugs ...

“Regional variations exist in antipsychotic and antidementia medication use among nursing home residents with dementia, suggesting the need for evidence-based protocols to guide the use of these ...